We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+15.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$214M
AUM Growth
+$8.02M
Cap. Flow
-$22.7M
Cap. Flow %
-10.61%
Top 10 Hldgs %
48%
Holding
89
New
17
Increased
13
Reduced
25
Closed
14

Top Buys

Rank Stock Value
1
VYNE icon
VYNE Therapeutics
VYNE
+$3.38M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.82M
3
KURA icon
Kura Oncology
KURA
+$1.91M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$1.63M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$1.38M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.44M
2
ARGX icon
argenx
ARGX
+$2.88M
3
PODD icon
Insulet
PODD
+$2.82M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.72M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 85.47%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INDP icon
26
Indaptus Therapeutics
INDP
$243M
$2.5M 1.17%
+254
New +$2.82M
BEAT
27
DELISTED
BioTelemetry, Inc.
BEAT
$2.45M 1.15%
54,500
-15,000
-22% -$598K
ARGX icon
28
argenx
ARGX
$55.2B
$2.15M 1.01%
25,949
-32,181
-55% -$2.88M
SCYX icon
29
SCYNEXIS
SCYX
$37.4M
$2.09M 0.98%
15,944
-4,517
-22% -$538K
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.92M 0.9%
+59,200
New +$1.63M
WVE icon
31
Wave Life Sciences
WVE
$1.12B
$1.83M 0.86%
47,900
+3,500
+8% +$151K
ARDX icon
32
Ardelyx
ARDX
$1.24B
$1.75M 0.82%
472,859
+225,000
+91% +$1.04M
FOMX
33
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.69M 0.79%
338,000
+2,500
+0.7% +$12.9K
LRMR icon
34
Larimar Therapeutics
LRMR
$377M
$1.67M 0.78%
+13,615
New +$1.16M
MGNX icon
35
MacroGenics
MGNX
$233M
$1.62M 0.76%
78,305
-4,800
-6% -$108K
AGTC
36
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.56M 0.73%
421,000
– –
IMDZ
37
DELISTED
Immune Design Corp.
IMDZ
$1.5M 0.7%
328,500
– –
INCY icon
38
Incyte
INCY
$25.4B
$1.44M 0.67%
21,500
+6,500
+43% +$445K
CYPH
39
Cypherpunk Technologies Inc
CYPH
$63.9M
$1.36M 0.64%
15,164
-4,836
-24% -$396K
DRNA
40
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.35M 0.63%
+110,000
New +$1.38M
NTUS
41
DELISTED
Natus Medical Inc
NTUS
$1.31M 0.61%
37,900
– –
PRQR icon
42
ProQR Therapeutics
PRQR
$246M
$1.25M 0.59%
171,351
-59,419
-26% -$300K
TVRD
43
Tvardi Therapeutics
TVRD
$20.2M
$1.2M 0.56%
1,745
-861
-33% -$438K
JNJ icon
44
Johnson & Johnson
JNJ
$640B
$1.14M 0.53%
9,400
– –
CDTX
45
DELISTED
Cidara Therapeutics
CDTX
$1.11M 0.52%
10,638
+9,481
+819% +$895K
NERV icon
46
Minerva Neurosciences
NERV
$191M
$1.08M 0.51%
16,359
-5,028
-24% -$305K
ARQL
47
DELISTED
Arqule Inc
ARQL
$1.04M 0.49%
188,664
-296,320
-61% -$1.13M
ADXS
48
DELISTED
Advaxis Inc
ADXS
$1.01M 0.47%
46,467
– –
NVAX icon
49
Novavax
NVAX
$1.21B
$1M 0.47%
+37,500
New +$1.27M
OBSV
50
DELISTED
ObsEva SA Ordinary Shares
OBSV
$984K 0.46%
64,977
+58,192
+858% +$773K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, DAFNA Capital Management held 89 positions worth $214M, up 3.9% from $206M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $22.7M in Q2 2018, closing 14 positions and reducing 25 holdings. Its most notable exit was Insulet, an estimated $2.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in VYNE Therapeutics worth $2.53M.

  • DAFNA Capital Management's largest Q2 2018 buy was VYNE Therapeutics: 87 shares worth $2.53M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2018, an estimated $1.91M increase.
  • DAFNA Capital Management's biggest Q2 2018 reduction was Loxo Oncology, Inc, cutting an estimated $3.44M.
  • DAFNA Capital Management fully exited Insulet in Q2 2018, selling an estimated $2.82M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $214M portfolio in Q2 2018.
  • DAFNA Capital Management opened 17 new positions and closed 14 in Q2 2018.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $214M.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.